Context Therapeutics Extends Cash Runway as It Awaits Key Clinical Data
Event summary
- Context Therapeutics reported $66.0M in cash and equivalents as of December 31, 2025, down from $94.4M a year earlier.
- The company expects its current runway to extend into mid-2027, despite a net loss of $36.1M for 2025.
- Phase 1a interim data for CTIM-76 (CLDN6 x CD3) and CT-95 (MSLN x CD3) are anticipated in June and September 2026, respectively.
- First patient dosing for the CT-202 Phase 1 trial is planned for Q3 2026.
The big picture
Context Therapeutics is navigating a critical phase in its development, with multiple clinical readouts on the horizon. The company's ability to extend its cash runway into mid-2027 provides a buffer for these milestones, but investors will be closely watching whether the data supports continued advancement. In an increasingly competitive biopharmaceutical landscape, the success of CTIM-76 and CT-95 could position Context as a key player in the T cell-engaging bispecific antibodies space.
What we're watching
- Clinical Milestones
- Whether the interim data for CTIM-76 and CT-95 in mid-2026 will demonstrate sufficient efficacy and safety to advance development.
- Financial Sustainability
- The pace at which Context Therapeutics burns through its remaining cash reserves and whether additional funding will be required before mid-2027.
- Pipeline Progression
- How the initiation of the CT-202 Phase 1 trial in Q3 2026 will impact the company’s strategic focus and resource allocation.
Our editorial coverage:
Related topics